:brightness(0))
:brightness(0))
:brightness(0))
:brightness(0))
Where research becomes impact
:brightness(0))
Reconstitution and solubility of PLLA-LASYNPRO™ using in vitro analysis
PLLA-LASYNPRO™ exhibited rapid, uniform reconstitution, resulting in a homogeneous milky-white solution with no foam formation.
Microscopic analysis revealed consistent particle morphology. The small, uniform, and spherical particles may contribute to a reduced inflammatory reaction in aesthetic applications.
Source: Comparative Analysis of Reconstitution and Solubility of Two Poly-L-Lactic Acid Fillers for Medical Applications Pawel Kubik , Wojciech Gruszczyński and Monika Filipowska, Polymers (Basel). 2025 Jun 27;17(13):1778. https://www.mdpi.com/2073-4360/17/13/1778
The unique potential of JULÄINE™
A new publication highlights the unique potential of JULÄINE™, a PLLA-based injectable (PLLA-LASYNPRO™), developed to activate collagen and extracellular matrix regeneration – without provoking significant inflammation.
Initial clinical findings demonstrate clear improvements in facial volume and skin texture – particularly in the nasolabial region – reinforcing JULÄINE™’s position within regenerative aesthetics.
Source: Facial Rejuvenation With an Innovative Poly-l-Lactic Acid (Juläine) for Nasolabial Folds: Interim Data Analysis of a Prospective, Non-Randomized, Multicenter, Open-Label Spanish Study, Urdiales-Gálvez F., Benítez P.A., Díaz https://pubmed.ncbi.nlm.nih.gov/40135677/
The safety profile of JULÄINE™
A recent survey conducted with 36 practitioners across Spain, aimed to assess the safety of Juläine. It found that most respondents (47.2%) had 3-6 months of experience with the product. Despite concerns about potential nodule formation with PLLA fillers, the incidence of nodules was considered extremely rare or absent, with most mild adverse events being transient. These findings align with existing literature, indicating that the majority of patients did not experience significant adverse events.
